Citations

Clear

4 citation(s) found for "Scott, Phillip".

Coagulation test changes associated with acute normovolemic hemodilution in cardiac surgery
Nuttall, Gregory A. , Mauermann, William J., Schroeder, Darrell R. , Scott, Phillip D., Smith, Mark M , Schroeder, Darrell , Smith, Bradford B. , Smith, Mark M.

Mayo Clinic

Journal of Cardiac Surgery | April 5, 2020 | Volume: 35 | Issue: 5 | Pages: 1043-1050

10.1111/jocs.14532 | PMID 32248625 Get It

ECMO Cannulation Controversies and Complications
Stulak, John M., Burkhart, Harold M. , Barnes, Roxann D., Scott, Phillip D., Schears, Gregory J. , Dearani, Joseph A.

Mayo Clinic

Seminars in Cardiothoracic and Vascular Anesthesia | September 7, 2009 | Volume: 13 | Issue: 3 | Pages: 176-182

10.1177/1089253209347943 | PMID 19736214 Get It

Advances in extracorporeal life support have expanded indications for use extending beyond patients undergoing cardiac surgery. The approach to cannulation in patients requiring extracorporeal membrane oxygenation should be individualized and based on the specific clinical scenario in which the need arises. Adherence to proper techniques of vessel visualization, exposure, and cannulation along with accurate placement of cannulae will optimize flows and minimize complications in this setting. Patients in need of mechanical circulatory support require input from a multidisciplinary team approach with systematic clinical evaluation to optimize outcome. If hemodynamics do not initially permit the successful separation from mechanical support, then a systematic search for potentially reversible patient and/ or pump related factors should be undertaken. The success of this therapy is predicated on patient selection, a multidisciplinary team approach in the intensive care unit, adherence to precise technical principles, and repeated patient evaluation.
Update on Safety Equipment for Extracorporeal Life Support (ECLS) Circuits
Riley, Jeffrey B., Scott, Phillip D., Schears, Gregory J.

Mayo Clinic

Seminars in Cardiothoracic and Vascular Anesthesia | August 31, 2009 | Volume: 13 | Issue: 3 | Pages: 138-145

10.1177/1089253209347895 | PMID 19720681 Get It

Though much has been surveyed and written about the equipment aspects of extracorporeal life support (ECLS) in the past 10 years, there is value in reviewing the use and nonuse of multiple safety devices and techniques. Minimally equipped ECLS circuits for adult and pediatric bridge to decision during cardiac and respiratory failure are rapidly gaining popularity to maintain simplicity and portability. ECLS circuits employed for long-term therapy are outfitted differently and should include more safety devices. The purpose of this review is to compare and contrast the spectrum of minimally equipped ECLS circuits to circuits with maximum flexibility and safety device protection. Due to the lack of high-level, well-controlled scientific studies regarding ECLS equipment and safety devices, this study reviews the basis for how we use ECLS circuits and devices in our institution to provide safe patient support.
The C ombined Approach to L ysis Utilizing E ptifibatide a nd r t-PA in Acute Ischemic Stroke
Pancioli, Arthur , Brott, Thomas G. , Tomsick, Thomas A. , Bean, Judy A., Zoppo, Gregory del, Kleindorfer, Dawn , Woo, Daniel , Khatri, Pooja , Castaldo, John , Frey, James L., Gebel, James, Kidwell, Chelsea S., Kwiatkowski, Thomas , Libman, Richard , Mackenzie, Richard S., Starkman, Sidney , Thurman, R. Jason, Jauch, Edward C. , Liebeskind, David S. , Meurer, William J. , Buck, Brian , Broderick, Joseph P. , Khoury, Jane , Kasner, Scott Eric , Scott, Phillip , Liebeskind, David S. , Buck, Brian H , Khatri, Pooja

Mayo Clinic

Stroke | September 5, 2008 | Volume: 39 | Issue: 12 | Pages: 3268-3276

10.1161/strokeaha.108.517656 | PMID 18772447 Get It

Background and Purpose— Multiple approaches are being studied to enhance the rate of thrombolysis for acute ischemic stroke. Treatment of myocardial infarction with a combination of a reduced-dose fibrinolytic agent and a glycoprotein (GP) IIb/IIIa receptor antagonist has been shown to improve the rate of recanalization versus fibrinolysis alone. The c ombined approach to l ysis utilizing e ptifibatide a nd r ecombinant tissue-type plasminogen activator (rt-PA) (CLEAR) stroke trial assessed the safety of treating acute ischemic stroke patients within 3 hours of symptom onset with this combination. Methods— The CLEAR trial was a National Institutes of Health/National Institute of Neurological Disorders and Stroke–funded multicenter, double-blind, randomized, dose-escalation and safety study. Patients were randomized 3:1 to either low-dose rt-PA (tier 1=0.3 mg/kg, tier 2=0.45 mg/kg) plus eptifibatide (75 μg/kg bolus followed by 0.75 μg/kg per min infusion for 2 hours) or standard-dose rt-PA (0.9 mg/kg). The primary safety end point was the incidence of symptomatic intracerebral hemorrhage within 36 hours. Secondary analyses were performed regarding clinical efficacy. Results— Ninety-four patients (40 in tier 1 and 54 in tier 2) were enrolled. The combination group of the 2 dose tiers (n=69) had a median age of 71 years and a median baseline National Institutes of Health Stroke Scale (NIHSS) score of 14, and the standard-dose rt-PA group (n=25) had a median age of 61 years and a median baseline NIHSS score of 10 ( P =0.01 for NIHSS score). Fifty-two (75%) of the combination treatment group and 24 (96%) of the standard treatment group had a baseline modified Rankin scale score of 0 ( P =0.04). There was 1 (1.4%; 95% CI, 0% to 4.3%) symptomatic intracranial hemorrhage in the combination group and 2 (8.0%; 95% CI, 0% to 19.2%) in the rt-PA–only arm ( P =0.17). During randomization in tier 2, a review by the independent data safety monitoring board demonstrated that the safety profile of combination therapy at the tier 2 doses was such that further enrollment was statistically unlikely to indicate inadequate safety for the combination treatment group, the ultimate outcome of the study. Thus, the study was halted. There was a trend toward increased clinical efficacy of standard-dose rt-PA compared with the combination treatment group. Conclusions— The safety of the combination of reduced-dose rt-PA plus eptifibatide justifies further dose-ranging trials in acute ischemic stroke.